TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean number of daily doses of ProAir® Digihaler™
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean number of daily doses of AirDuo® Digihaler™
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median number of daily doses of ProAir® Digihaler™
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median number of daily doses of AirDuo® Digihaler™
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Menopause Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-reported home adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive performance assessment score change (code substitution)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance assessment score change (reaction time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oculometric assessment score change (saccades)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Solicited and unsolicited adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of participants experiencing treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in monthly countable seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of new chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Vaginal Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Burning Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain During Intercourse (Dyspareunia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vaginal Health Index Score (VHIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sexual Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of monozygosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of changed chorionicity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of late TTTS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average dose value (Gy) of tumor liver and healthy liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of immediate pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of CADx support tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Psoriasis Area Severity Index Sum of Scores (Local PASI SOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: hSBA antibody titers ≥ 1:8 against meningococcal serogroups A, C, Y, and W
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants who achieved ≥4-fold rise in antibody titers over baseline measured by hSBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hSBA meningococcal serogroups A, C, Y, and W vaccine seroresponse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Change in Pain Relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of patients receiving actionable genomic variant treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Primary vascular patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Sexual and Reproductive Health and Rights Knowledge Survey Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in 30 day readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the serum concentration time curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration time curve (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed maximum serum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LAMP1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intratracheal bleeding control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Itch on the 5-D Itch Scale at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline in Muscle Cramps on the Visual Analog Scale at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Comfort on the Hemodialysis Comfort Scale -Version II at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Myocardial/skeletal muscle metabolism and energetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes per week after desmopressin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients developed jaundice
Endpoint domain: Adverse events/effects
Primary endpoint: Subject Captured Seizure Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of DFU recurrence after completing or withdrawing from the ON101CLCT02 trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostatic Performance at 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional evaluation of the shoulder and upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: integrated radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vizüel Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Herth Hope Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuropathic Pain Impact on Quality of Life Questionnaire (NePIQOL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: shoulder range of motions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disabilities of the arm, shoulder and hand questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: constant murley questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Medication Adherence on the ARMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication management self-efficacy on the MUSE Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PML understanding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in parenthood intentions
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Treatment effectiveness in wart removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pancreatic fistula occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Illness Intrusiveness Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency, causality, severity, and expectedness of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Death or hospitalization due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Development of significant cardiac arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle relaxation recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline number of days of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change from baseline Dialyzer clearance of urea (Kt/V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lipid profiles of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Return of Bowel Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of approved patients recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of recruited patients retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who receiving the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Spinal Cord Independence Measure-Self Reported (SCIM-SR) change after six weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in obsessive-compulsive disorder symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in compulsive hair pulling symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in compulsive skin picking symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in activation in the right inferior frontal cortex (rIFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of POC testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface electromyography at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface electromyography at maximum voluntary contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy as Assessed by Occlusion Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as Assessed by Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Central target engagement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral target engagement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent post-concussive symptoms modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear avoidance modulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Parental Burnout Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression Anxiety Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Caregiver Difficulties Scale
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Number of Participants with Treatment Emergent Grade 3 and Grade 4 Hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Real vaccination status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion of wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pain and degree of interference with feeling and function
Endpoint domain: Adverse events/effects
Primary endpoint: Device and Procedure serious adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Radiologic local control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Arterial Blood Pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in relative brachial artery flow-mediated dilation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in triglycerides (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of acute graft-versus-host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Confidence of Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in postprandial glycemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung function (FVC) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Biochemical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol and other drug (AOD) use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antisocial/prosocial behavior and mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Ankle Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Six minutes walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time up and go (TUG) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Pediatric Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Gross Motor Function Measure (GMFM) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow of arteriovenous fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measurement of uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Swelling size changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of volunteers with blood-stage parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of volunteers protected against controlled human malaria infection immunisation with the GA2 parasite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and magnitude of adverse events in Phase 1 and Phase 2
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with an offer of a new patient appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of Base Tone of Pelvic Floor Muscles (EMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of electromyography of Pelvic Floor Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Grip Strength Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP continuation 1 month after re-start
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of back pain after epiduroscopic procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of leg pain after epiduroscopic procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bold fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline CANTAB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Wechsler Memory Scale - Logical Memory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline SSTICS-B score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Cognitive Motivation Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline DACOBS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Healing post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Endothelial Colony Forming Cells (ECFC) from cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Human Umbilical Vein Endothelial Cells (HUVEC) from cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Burnout Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of SARS-CoV-2 viral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Assessment of itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinically significant change from baseline in vital signs values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant change in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type, incidence, severity, seriousness, and relatedness of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with abnormal Electrocardiogram readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numerical rating scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Pain-related fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean milk volume of expressed milk (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth of preterm low birth weight neonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spread of contrast to mandibular nerve branches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of establishment of exploitable tumor organoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Extent of usage documented by the ChatGPT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subjective experiences related to behavioural, cognitive, and affective engagement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in extracellular volume (ECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in myocardial T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in myocardial metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early asthmatic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of eligible participants that consent to being a part of the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Likert scale 1 to 5 of patient satisfaction with treatment experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of immune cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Alzheimer disease biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Edinburgh Observational Gait Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Status Assessment (Montreal Cognitive Assessment: MoCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evaluation of Neck Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Glucose stability measured by Continuous Glucose Monitoring (CGM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose stability measured by hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 28 day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of standardized use of antibacterial/antifungal drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: European Quality of Life-5 Dimensions (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Erythrocyte membrane levels of DHA and AA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ray Auditory Verbal Learning Test (RAVLT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in UPDRS III score without medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of volunteers with a ≥ grade 3 solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with ≥ grade 3 and/or vaccine related unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Recording of fast ripples (FRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Single neuron activity in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes